What is already known about this topic?
Recurrence of COVID-19 symptoms and positive SARS-CoV-2 test results have been reported after completion of Paxlovid oral antiviral treatment for COVID-19, but real-world evidence of severe illness following Paxlovid is lacking.
What is added by this report?
COVID-19–related hospital admissions and emergency department (ED) encounters occurring 5–15 days after Paxlovid treatment were described using data from a large integrated health care system. Reports of such hospitalizations or ED encounters occurred infrequently, representing <1% of Paxlovid-treated patients over the study period.
What are the implications for public health practice?
When administered as an early-stage treatment, Paxlovid might prevent COVID-19–related hospitalization among persons with mild-to-moderate COVID-19 who are at risk for progression to severe disease.
Entire content available on: https://www.cdc.gov/mmwr/volumes/71/wr/mm7125e2.htm
Lingua
IngleseTipologia
Articoli scientifici/ReviewsArgomento
Gestione Clinica Covid-19Profilo
Ospedale/LTCF Cure primariePaese
USA Canada America del sud America centrale Caraibi Medio oriente Sud Pacifico Cina India Indocina Singapore Europa e UK Oceania Africa